MedTrace Logo

A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

NCT07093814 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-01-02

No results posted yet for this study

Summary

This study is an open-label, single-arm Phase I/II clinical trial with the primary objective of evaluating the safety, tolerability, and efficacy of VRT106 in patients with recurrent/progressive glioblastoma.

Conditions

Interventions

DRUG

VRT106

VRT106,intravenous

Sponsors & Collaborators

  • Guangzhou Virotech Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Chengcheng Guo · Sun Yat-sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-02
Primary Completion
2028-12-31
Completion
2029-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07093814 on ClinicalTrials.gov